Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Bum-Joon Park PhD

Bum-Joon Park PhD

CEO, PRG Science & Technology; Professor, Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Korea

Dr. Bum-Joon Park is a professor in the Department of Molecular Biology at Pusan University and the CEO of the company, PRG Science and Technology. He majorly studied Cancer Biology during Ph.D. course and postdoctoral training. After being employed as an assistant professor at Pusan University, he focused on finding target sites for the therapeutic treatment of several diseases related to aging, tumor formation, neurodegeneration, etc. until now. Those research made him find some candidate drugs for HGPS, NF2, ALS, etc. This could make him establish a biotech company for therapeutics, PRG S&T in Busan South Korea on September 2017 (www.prgst.com/eng).

Recent Contributions to PracticeUpdate:

  1. Brigatinib in Patients With NF2-Related Schwannomatosis With Progressive Tumors

Most Read This Week

Recently Updated